The conclusions of the Ib safety trial required by the EMA (to demonstrate safety prior to the start of Phase IIb/III) were presented in ESMO 2021 Congress in Paris selected as an Oral Presentation, showed that the dosage used for our trial was 12g/day of 2OHOA is well tolerated and safe in combination with the SoC. The results were presented by Dr. Balañà, a member of the Ethics Board of the CLINGLIO project and IP from the Ib phase trial.
For more information on the results:
Balañà et al. 346MO - Safety of idroxioleic acid in combination with standard of care (temozolomide and/or radiation therapy) in newly diagnosed glioblastoma patients: A phase Ib trial. Annals of Oncology (2021) 32 (suppl_5): S516-S529. 10.1016/annonc/annonc674